AU2014372562B2 - A method of making adenovirus and corresponding plasmids - Google Patents

A method of making adenovirus and corresponding plasmids Download PDF

Info

Publication number
AU2014372562B2
AU2014372562B2 AU2014372562A AU2014372562A AU2014372562B2 AU 2014372562 B2 AU2014372562 B2 AU 2014372562B2 AU 2014372562 A AU2014372562 A AU 2014372562A AU 2014372562 A AU2014372562 A AU 2014372562A AU 2014372562 B2 AU2014372562 B2 AU 2014372562B2
Authority
AU
Australia
Prior art keywords
site
adenovirus
arm
gene
restriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014372562A
Other languages
English (en)
Other versions
AU2014372562A1 (en
Inventor
Alice Claire Noel BROWN
Tamara NICOLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Akamis Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/072919 external-priority patent/WO2015059303A1/en
Application filed by Akamis Bio Ltd filed Critical Akamis Bio Ltd
Publication of AU2014372562A1 publication Critical patent/AU2014372562A1/en
Application granted granted Critical
Publication of AU2014372562B2 publication Critical patent/AU2014372562B2/en
Assigned to Akamis Bio Limited reassignment Akamis Bio Limited Request to Amend Deed and Register Assignors: PSIOXUS THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014372562A 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids Active AU2014372562B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1322851.5 2013-12-23
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
AUPCT/EP2014/072919 2014-10-24
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes
PCT/EP2014/079162 WO2015097220A1 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Publications (2)

Publication Number Publication Date
AU2014372562A1 AU2014372562A1 (en) 2016-07-21
AU2014372562B2 true AU2014372562B2 (en) 2020-11-26

Family

ID=50114629

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014372562A Active AU2014372562B2 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Country Status (10)

Country Link
US (1) US10472648B2 (cg-RX-API-DMAC7.html)
JP (2) JP6804133B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160102024A (cg-RX-API-DMAC7.html)
CN (1) CN106062199B (cg-RX-API-DMAC7.html)
AU (1) AU2014372562B2 (cg-RX-API-DMAC7.html)
CA (1) CA2934015A1 (cg-RX-API-DMAC7.html)
GB (1) GB201322851D0 (cg-RX-API-DMAC7.html)
IL (1) IL246235B (cg-RX-API-DMAC7.html)
SG (1) SG11201604801WA (cg-RX-API-DMAC7.html)
WO (1) WO2015097220A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3021859T3 (cg-RX-API-DMAC7.html) 2013-10-25 2018-04-28
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
WO2017103291A1 (en) * 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US20200017862A1 (en) * 2017-03-07 2020-01-16 University Of North Carolina Charlotte Systems and methods for single-strand break signaling and repair in a cell-free system
US11253608B2 (en) 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
JP7394628B2 (ja) * 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
EA202090700A1 (ru) * 2017-10-16 2020-10-21 Глаксосмитклайн Байолоджикалс Са Компетентные по репликации аденовирусные векторы
CN108424932B (zh) * 2018-03-13 2021-01-05 北京多赢时代转化医学研究院 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113186151A (zh) * 2021-03-03 2021-07-30 郑州大学 一种提高腺病毒产毒能力的单克隆细胞、细胞库及制备方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
CN1221666C (zh) * 2003-09-02 2005-10-05 广东省人民医院 腺病毒穿梭质粒及其构建方法
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
DE602005025340D1 (de) * 2004-05-26 2011-01-27 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US20090208924A1 (en) * 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) * 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
CA2812093A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN105407902A (zh) 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI, 0, Derwent World Patents Index, vol. 2012, no. 67, Database accession no. 2012-L80326, & CN102586327 A 20120718 (UNIV SHANXI NORMAL) *
HOFFMANN DENNIS ET AL, "Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli", BMC BIOTECHNOLOGY, (2006-08-03), vol. 6 *
JOSEPHINE M. JANSSEN ET AL, "Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells", THE JOURNAL OF GENE MEDICINE, (2013-01-01), vol. 15 *

Also Published As

Publication number Publication date
SG11201604801WA (en) 2016-07-28
WO2015097220A1 (en) 2015-07-02
CA2934015A1 (en) 2015-07-02
JP2017501695A (ja) 2017-01-19
CN106062199A (zh) 2016-10-26
JP2021040651A (ja) 2021-03-18
JP7104994B2 (ja) 2022-07-22
CN106062199B (zh) 2019-12-03
US20160319304A1 (en) 2016-11-03
IL246235A0 (en) 2016-07-31
AU2014372562A1 (en) 2016-07-21
GB201322851D0 (en) 2014-02-12
US10472648B2 (en) 2019-11-12
KR20160102024A (ko) 2016-08-26
IL246235B (en) 2020-02-27
JP6804133B2 (ja) 2020-12-23

Similar Documents

Publication Publication Date Title
AU2014372562B2 (en) A method of making adenovirus and corresponding plasmids
US11672874B2 (en) Methods and compositions for genomic integration
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
AU2018347421B2 (en) Transgenic selection methods and compositions
AU2019204982B2 (en) Recombinant HCMV and RhCMV Vectors and Uses Thereof
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
AU2019284926B2 (en) Engineered cascade components and cascade complexes
AU2017371944B2 (en) Adenovirus polynucleotides and polypeptides
KR20220004959A (ko) 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
KR20100109914A (ko) 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
TW202523847A (zh) 經修飾之腺病毒
KR20210093862A (ko) 유전자 요법 벡터를 제작하기 위한 조성물 및 방법
CN111733174B (zh) 一种分离的核酸分子及其用途
AU2018351308B2 (en) Replication competent adenoviral vectors
KR20240037192A (ko) 게놈 통합을 위한 방법 및 조성물
KR20240029020A (ko) Dna 변형을 위한 crispr-트랜스포손 시스템
KR20230153405A (ko) Il-15를 암호화하는 아데노바이러스
KR20250136930A (ko) 사람 파필로마바이러스 백신 및 이의 용도
CN114657213A (zh) 一种猪急性腹泻综合征冠状病毒人工染色体重组载体及其构建方法和应用
CN117157109A (zh) 腺病毒基因疗法载体
CN113260704B (zh) CYP4V2和RdCVF在制备药物中的用途
CN116323942A (zh) 用于基因组编辑的组合物及其使用方法
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
KR20230031929A (ko) 고릴라 아데노바이러스 핵산 서열 및 아미노산 서열, 이들을 함유하는 벡터, 및 이의 용도
JP2002153275A (ja) スプーマウイルスプラスミドおよびその利用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AKAMIS BIO LIMITED

Free format text: FORMER NAME(S): PSIOXUS THERAPEUTICS LIMITED